Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Zepbound is a newer weight loss medication joining the ranks of Wegovy and Saxenda. It’s a brand name for tirzepatide, which manufacturers also sell as a drug for type 2 diabetes under the name ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...